Haemato AG Net Assets

Latest as of : €- EUR ≈ $- USD

Haemato AG net assets. Based on the latest financial reports, Haemato AG (HAEK) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore HAEK year-over-year net asset growth to track the company's year-over-year net asset growth rate.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€-
% of Total Assets	0%
Annual Growth Rate	1.69%
5-Year Change	N/A
10-Year Change	N/A
Growth Volatility	N/A

Net Assets of Haemato AG (2021–2022)

Net assets of Haemato AG from 2021 to 2022. This chart illustrates how Haemato AG's net assets have evolved over time, based on quarterly financial data. See HAEK net asset quality index to measure how much of total assets are equity-financed.

Annual Net Assets for Haemato AG (2021–2022)

The table below shows the annual net assets of Haemato AG from 2021 to 2022. For live market cap and overall valuation, see HAEK company net worth.

Year	Net Assets	Change
2022-12-31	€147.17 Million ≈ $172.06 Million	+1.69%
2021-12-31	€144.73 Million ≈ $169.20 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Haemato AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 9.0% over the analyzed period, indicating profitable operations and earnings retention.

Haemato AG Net Assets Breakdown (December 2022)

Haemato AG net assets breakdown by equity component as of December 2022.

Component	Amount	Percentage
Retained Earnings	€29.46 Million	20.02%
Other Components	€117.71 Million	79.98%
Total Equity	€147.17 Million	100.00%

Haemato AG Competitors by Market Cap

The table below lists competitors of Haemato AG ranked by their market capitalization.

Company	Market Cap
Mitrajaya Holdings Bhd KLSE:9571	$64.92 Million
Tailyn Technologies TWO:5353	$64.93 Million
BQE Water Inc V:BQE	$64.94 Million
Powerlogics Co. Ltd KQ:047310	$64.96 Million
Garo AB ST:GARO	$64.89 Million
NEW ZEALAND RURAL F:8UK	$64.89 Million
Allcargo Terminals Ltd NSE:ATL	$64.88 Million
Kazia Therapeutics Ltd ADR NASDAQ:KZIA	$64.84 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Haemato AG's equity between the two most recent reporting periods.

Equity Growth Insights

From 2021 to 2022, total equity changed from 144,725,954 to 147,168,177, a change of 2,442,223 (1.7%).
Net income of 8,192,570 contributed positively to equity growth.
Dividend payments of 5,750,347 reduced retained earnings.

Equity Change Factors (2021 to 2022)

Factor	Impact	Contribution
Net Income	€8.19 Million	+5.57%
Dividends Paid	€5.75 Million	-3.91%
Total Change	€-	1.69%

Book Value vs Market Value Analysis

This analysis compares Haemato AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.45x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2021-12-31	€27.68	€12.70	x
2022-12-31	€28.14	€12.70	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Haemato AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 5.57%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.30%
• Asset Turnover: 1.41x
• Equity Multiplier: 1.20x
Recent ROE (5.57%) is above the historical average (5.04%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2021	4.51%	2.29%	1.57x	1.26x	€-7.94 Million
2022	5.57%	3.30%	1.41x	1.20x	€-6.52 Million

Industry Comparison

This section compares Haemato AG's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $9,729,794,157
Average return on equity (ROE) among peers: -99.76%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Haemato AG (HAEK)	€-	4.51%	N/A	$64.92 Million
SHANG.FOS.PHARM.GR.H YC 1 (08HH)	$56.62 Billion	4.21%	1.00x	$1.20 Billion
PEPTONIC MEDICAL (28L)	$47.09 Million	-78.27%	0.82x	$5.52 Million
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ)	$5.05 Billion	11.11%	0.41x	$692.11 Million
WEST ISLAND BRANDS INC. (39N0)	$3.27 Million	-157.21%	0.88x	$1.34 Million
HANSOH PHARMAC. HD-00001 (3KY)	$35.36 Billion	15.71%	0.13x	$22.06 Billion
AYURCANN HOLDINGS CORP. (3ZQ0)	$534.88K	-741.80%	26.77x	$97.35K
CERENO SCIENTIFIC AB B (4A1)	$201.51 Million	-13.72%	0.07x	$60.94 Million
MAPLE LEAF GREEN WORLD (4HV0)	$-8.83 Million	0.00%	0.00x	$504.30K
LORDS CO. WORLDW. HOLD. (4XM)	$-1.01 Million	0.00%	0.00x	$134.78K
RED LIGHT HOLLAND CORP. (4YX)	$20.26 Million	-37.64%	0.19x	$6.62 Million

About Haemato AG

HM:HAEK Germany Drug Manufacturers - Specialty & Generic

Market Cap

$77.64 Million

€66.41 Million EUR

Market Cap Rank

#20712 Global

#1875 in Germany

Share Price

€12.70

Change (1 day)

-2.31%

52-Week Range

€8.25 - €13.60

All Time High

€13.60